Focused Ultrasound Foundation

Thank You to Our 20th Anniversary Celebration Sponsors!

As we prepare for Celebrating Focused Ultrasound: The Future Is Now, November 11–13, we extend our sincere gratitude to the more than 70 sponsors whose generous support is helping make this event possible.

We also look forward to welcoming more than 40 industry exhibitors. Attendees are encouraged to visit the exhibits, connect with industry leaders, and learn about the latest advances in focused ultrasound technology.

Virtual registration is free and provides access to live sessions, virtual posters, and sponsor profiles. Register today: celebration.fusfoundation.org/register

Founded in 1999, Chongqing Haifu Technology Co. Ltd. is a world-leading innovator and manufacturer of noninvasive focused ultrasound treatment devices. Its Haifu System is available in over 30 countries and regions across Europe, Asia, Africa, and Latin America, and has been used to treat more than 360,000 patients worldwide.

In our recent interview, the company’s leadership shares insights into its history, global expansion, and vision for the future of focused ultrasound: ow.ly/nI4g51014Hp

Register Today!

The Foundation is pleased to co-sponsor a public workshop with the FDA on November 10 to explore the key considerations in the rapidly evolving field of transcranial ultrasound for neurological and psychiatric conditions.

Bringing together leading researchers, clinicians, and other stakeholders, the workshop will discuss key topics including important scientific knowledge and clinical experience, safety assessments, clinical trial design considerations, and the development of emerging applications such as neuromodulation and blood-brain barrier opening.

We encourage the focused ultrasound community and others interested in the field to attend this exciting event, either in person in McLean, Virginia, or virtually.

Registration is open through November 5. Learn more and register: ow.ly/MLOl51049gG

In our latest podcast episode, we speak with Jeffrey Coull, PhD, founder and CEO of @GreyMatterNeuro, who discusses the company's focused ultrasound system and why treatment-resistant depression was chosen as its initial clinical application:
Listen to the episode: ow.ly/Q3O35101vAo

The UK Foundation recently hosted its first symposium, bringing together nearly 120 attendees and 33 expert speakers to discuss the future of focused ultrasound in the UK. They highlighted research, clinical applications, emerging technologies, and more: ow.ly/ueW25103buM